Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Sabri, Osama; Sabbagh, Marwan N.; Seibyl, John; Barthel, Henryk; Akatsu, Hiroyasu; Ouchi, Yasuomi; Senda, Kohei; Murayama, Shigeo; Ishii, Kenji; Takao, Masaki; Beach, Thomas G.; Rowe, Christopher C.; Leverenz, James B.; Ghetti, Bernardino; Ironside, James W.; Catafau, Ana M.; Stephens, Andrew; Mueller, André; Koglin, Norman; Hoffmann, Anja; Roth, Katrin; Reininger, Cornelia; Schulz‐Schaeffer, Walter; Group, Florbetaben Phase 3 Study

doi:10.1016/j.jalz.2015.02.004

articleAlzheimer s & DementiaMar 27, 2015HYBRID OA

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

OSOsama Sabri MNMarwan N. Sabbagh JSJohn Seibyl HBHenryk Barthel HAHiroyasu Akatsu

Leipzig University · Banner Sun Health Research Institute · +22 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Evaluation of brain β-amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias.

Methods

Open-label, nonrandomized, multicenter, phase 3 study to validate the (18)F-labeled β-amyloid tracer florbetaben by comparing in vivo PET imaging with post-mortem histopathology.

Citation impact

603

total citations

FWCI: 30.38
Percentile: 100%
References: 33

Citations per year

Authors

24

Topics & keywords

Topics

Keywords

Histopathology
Senile plaques
Medicine
Positron emission tomography
Amyloid (mycology)
Pathology
Alzheimer's disease
Pet imaging

UN Sustainable Development Goals

Reduced inequalities

No related works found for this paper.